Premium
Aromatic Organic Compounds as Scaffolds for Metallocarboxypeptidase Inhibitor Design
Author(s) -
Fernández Daniel,
Avilés Francesc X.,
Vendrell Josep
Publication year - 2009
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/j.1747-0285.2008.00752.x
Subject(s) - chemistry , moiety , quinoline , quinazoline , docking (animal) , enzyme , naphthalene , stereochemistry , combinatorial chemistry , active site , ic50 , in vitro , biochemistry , organic chemistry , medicine , nursing
We have identified and characterized a set of quinoline, naphthalene and quinazoline derivatives as inhibitors of metallocarboxypeptidases, a class of metal‐dependent proteolytic enzymes. The aromatic organic compounds were selected from a high‐throughput screening survey and, with some exceptions, showed a good correlation between inhibitory potency and docking energy value. The in vitro inhibition tests gave K i values in the lower micromolar range for metallocarboxypeptidases with different specificities, and a tendency to behave as more powerful inhibitors of CPB was observed for most of the compounds tested. The kinetic results were further analyzed by structural analysis via molecular docking. The most potent aromatic organic inhibitor docks to human CPB mostly through burial of its hydrophobic moiety deep into the enzyme’s active site cleft and by interacting with the catalytic zinc ion. The significance of our results in designing inhibitors against disease‐related CPs from the identified ligands is examined herein.